VC
RPRX icon

Vestor Capital’s Royalty Pharma RPRX Stock Holding History

Vestor Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49K Sell
4,400
-79,288
-95% -$4.13M ﹤0.01% 270
2026
Q1 		$4.01M Buy
83,688
+71,688
+597% +$3.14M 0.29% 65
2025
Q4 		$3.28M Sell
12,000
-70,114
-85% -$2.67M 0.23% 55
2025
Q3 		$2.9M Buy
82,114
+76,478
+1,357% +$2.77M 0.19% 78
2025
Q2 		$94K Sell
5,636
-399,100
-99% -$13.2M 0.01% 197
2025
Q1 		$12.6M Buy
+404,736
New +$12.8M 1.04% 29

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vestor Capital's RPRX Position: Q2 2026 in Review

Vestor Capital reduced its Royalty Pharma (RPRX) stake by 95% in Q2 2026, selling an estimated $4.13M and leaving 4,400 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #270.

Vestor Capital first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $12.6M in Q1 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Vestor Capital held 4,400 shares of Royalty Pharma worth $49K as of Q2 2026.
  • Vestor Capital sold 79,288 Royalty Pharma shares in Q2 2026, an estimated $4.13M.
  • Royalty Pharma made up ﹤0.01% of Vestor Capital's portfolio in Q2 2026, its #270 holding.
  • Vestor Capital first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
  • Vestor Capital's Royalty Pharma position peaked at $12.6M in Q1 2025.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Vestor Capital's 13F filing for Q2 2026, filed 28 Jul 2026.